Antimicrobial peptides overcome bacterial biofilm resistance by disrupting EPS, quenching quorum sensing, and killing persister cells
Background
Antimicrobial resistance (AMR), exacerbated by resilient bacterial biofilms, presents a critical therapeutic challenge. Biofilms protect bacteria from standard antibiotics through extracellular polymeric substance (EPS) scaffolds, quorum sensing (QS) circuits, and metabolic dormancy. Current treatments often fail to penetrate these protective layers or eradicate dormant cells. Antimicrobial peptides (AMPs) offer a promising new class of antimicrobials, leveraging distinct mechanisms to circumvent established resistance pathways and specifically target these biofilm-specific defenses.
Study Design
This review offers a comprehensive overview of antimicrobial peptides (AMPs) as antibiofilm agents, integrating molecular principles with translational applications. It discusses challenges posed by the biofilm environment and how both natural and designed AMPs overcome these barriers by disrupting EPS structure, quenching QS communication, and killing metabolically dormant persister cells. The review also assesses synergistic AMP-antibiotic combinations, nanoparticle-AMP conjugates, and surface-functionalized coatings, and highlights peptide engineering using AI, ML, and multiomics for in silico design.
Results
The review demonstrates that AMPs overcome biofilm barriers through multiple mechanisms. They effectively disrupt extracellular polymeric substance (EPS) structures, quench quorum sensing (QS) communication, and kill metabolically dormant persister cells, which are typically resistant to conventional antibiotics. > AMPs show promise not only as monotherapies but also exhibit synergistic benefits when combined with traditional antibiotics, enhancing their therapeutic index and stability. Furthermore, innovative delivery strategies like nanoparticle-AMP conjugates and surface-functionalized coatings are highlighted for improving AMP efficacy and stability. The review emphasizes the burgeoning field of peptide engineering, noting the critical role of artificial intelligence (AI), machine learning (ML), and multiomics approaches in expediting the in silico design of novel synthetic peptides with enhanced antibiofilm properties. This multi-pronged approach addresses the complex resilience of biofilms.
Key Findings
- AMPs disrupt extracellular polymeric substance (EPS) scaffolds in bacterial biofilms.
- AMPs quench quorum sensing (QS) communication, a key biofilm survival mechanism.
- AMPs effectively kill metabolically dormant persister cells, which resist traditional antibiotics.
- Synergistic AMP-antibiotic combinations enhance therapeutic efficacy against biofilms.
AI/MLandmultiomicsare accelerating the in silico design of next-generation synthetic AMPs.
Why It Matters
Antimicrobial peptides (AMPs) offer a critical new strategy to combat antibiotic-resistant infections complicated by biofilms, a major clinical challenge. For clinicians, this review underscores the potential for AMPs to address treatment failures where conventional antibiotics are ineffective, particularly in chronic or device-associated infections. The exploration of synergistic combinations and advanced delivery systems (e.g., nanoparticle conjugates, surface coatings) suggests future protocols could involve multi-modal therapies, significantly improving efficacy and reducing resistance development. While direct human protocols are still emerging, the emphasis on AI/ML in peptide design accelerates the discovery of optimized AMPs, moving closer to clinically viable, stable, and potent antibiofilm agents.